 |
20 Diseases |  |
6 Trials |
|
6 Trials |  |
84 News |  |
| «12 |
- OvaRex (oregovomab) / CanariaBio
Trial withdrawal, Metastases: Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=0, Withdrawn, Sponsor: Gynecologic Oncology Group
Terminated --> Withdrawn
- Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
Trial initiation date, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 11, 2013
P2, N=66, Recruiting, Sponsor: University of Nebraska
Terminated --> Withdrawn Initiation date: Mar 2013 --> Sep 2013
- Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
Enrollment open, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 11, 2013
P2, N=66, Recruiting, Sponsor: University of Nebraska
Initiation date: Mar 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- | Viracept (nelfinavir) / ViiV Healthcare, Roche, OvaRex (oregovomab) / CanariaBio
New P2 trial, Metastases: Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Oct 8, 2013
P2, N=66, Recruiting, Sponsor: University of Nebraska
- ||||| OvaRex (oregovomab) / CanariaBio
New P2 trial, Metastases: A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer (clinicaltrials.gov) - May 29, 2012
P2, N=80, Recruiting, Sponsor: Quest PharmaTech Inc.